July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
P2X7 receptor in relation to glaucoma: Friend or Foe?
Author Affiliations & Notes
  • Julie Sanderson
    School of Pharmacy, University of East Anglia, Norwich, United Kingdom
  • Footnotes
    Commercial Relationships   Julie Sanderson, None
  • Footnotes
    Support  Norwich Glaucoma Research Fund, University of East Anglia, The Humane Research Trust
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4200. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Julie Sanderson; P2X7 receptor in relation to glaucoma: Friend or Foe?. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4200.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The P2X7 receptor is expressed in the retina, associated with multiple cell types including Müller cells, microglia and retinal ganglion cells (RGCs). Activation of the RGC P2X7R leads to ATP-mediated excitotoxic cell death and the P2X7R is implicated in RGC degeneration in glaucoma. Indirect mechanisms may also contribute P2X7R-mediated RGC death and neuroinflammation following P2X7R-mediated cytokine release may also have a role to play. For example, in the ex vivo human retina, P2X7R stimulation causes secretion of IL-1β. IL-1β is a pro-inflammatory cytokine that is associated with neurodegeneration; it is, however, also reported to be neuroprotective. IL-10 is an anti-inflammatory cytokine; this is also secreted by the ex vivo human retina in response to P2X7R activation. Whether the P2X7R is a “friend” or “foe” in relation to RGC degeneration in glaucoma will be discussed.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.